Premium
P1‐254: Early detection of hereditary cerebral amyloid angiopathy with Pittsburgh Compound B
Author(s) -
Johnson K.A.,
Grabowski T.J.,
Gurol M.E.,
Skehan M.E.,
Nandigam R.N.K.,
Becker J.A.,
Garcia-Alloza M.,
Prada C.,
Frosch M.P.,
Rosand J.,
Smith E.E.,
Greenberg S.M.
Publication year - 2008
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2008.05.844
Subject(s) - pittsburgh compound b , cerebral amyloid angiopathy , pathology , white matter , amyloid (mycology) , vascular dementia , dementia , medicine , magnetic resonance imaging , disease , radiology
ing to 10-fold cross validation. The index also reflects the progression of the disease. First indications are that about 30% of the subjects respond to treatment, resulting in a delay of progression for about 6-9 months. Conclusions: In conclusion, this tool, which constitutes a surrogate marker, can be used as a significant part of the current diagnostic process for Alzheimer’s disease. The individual’s EEG can be measured anywhere and sent over the internet for analysis. The classification result and its confidence interval are sent back in a report. The technique can be used for monitoring the progression of AD and seems to be useful in evaluating the effect of treatment of cholinesterase inhibitors. Further research should aim at other types of intervention.